KANUMA™ is a hydrolytic lysosomal cholesteryl ester and triacylglycerol-specific enzyme indicated for the treatment of patients with a diagnosis of Lysosomal Acid Lipase (LAL) deficiency
IPN is a facilitator under Patient Assistance Programs. Expertise in Specialty Pharmaceutical distribution having its PAN India presence in Mumbai, Kolkata, Hyderabad, Chennai, Ahmedabad, Delhi, Bangalore, Srinagar, Jammu, Jaipur, Chandigarh, Ludhiana, Noida, Gurgaon, lucknow, north East and Pune and other cities in India. with over 20 years of domain experience.
For procurement cost of KANUMA (sebelipase alfa) injection brand in India, sold by indian drug manufacturer. Please call at M: +91 9811747774 (Mr. Tarun) / 9891296838 (Mr. Neeraj) or Email Us to know more details about the KANUMA (sebelipase alfa) injection medicine cost price in India.
The order for KANUMA (sebelipase alfa) injection will be confirmed only after the receipt of valid prescription of doctor and import permit if applicable.
Sebelipase alfa is used to treat lysosomal acid lipase deficiency. This is a life-threatening genetic disorder that can damage major organs in the body and lead to early death. Sebelipase alfa replaces the missing enzyme when the body does not have enough of its own.
KANUMA (sebelipase alfa) injection, for intravenous use Initial U.S. Approval: 2015
Generic Name: sebelipase alfa
Injection: 20 mg/10 mL (2 mg/mL) solution in single-use vials.
IPN helps patients, doctors and hospitals as a facilitator to import prescription medicine brand KANUMA (sebelipase alfa) injection on prescription and Import License in Patient's Name only.
For overseas patients, KANUMA (sebelipase alfa) injection can be made available in Send your enquiry to find KANUMA (sebelipase alfa) injection in China, Cambodia, Indonesia, Malaysia, the Philippines, Singapore, Thailand, Vietnam, Hong Kong. UAE Iraq, Iran, Saudi Arabia, Jordan, Mexico, Argentina, Brazil, Chile, Colombia, Peru, Venezuela. Europe – Romania, Switzerland, Georgia, Turkey, Italy, UK, Ukraine, Azerbaijan, Latvia, Poland, Slovakia. Russia CIS – Armenia, Kazakhstan, Moldova, Tajikistan, Turkmenistan, Uzbekistan, Mongolia, Algeria, Mauritius, Uganda, Zimbabwe. Australia and New Zealand.
For KANUMA (sebelipase alfa) injection Indications And Usage, Dosage And Administration, Dosage Forms And Strengths and Drug Interactions For More Details
ADDING MULTIMEDIA FDA Approves Kanuma™ (sebelipase alfa) for the Treatment of Patients with Lysosomal Acid Lipase Deficiency (LAL-D) For More Details
European Commission Grants Marketing Authorization for Kanuma™ (sebelipase alfa) for the Treatment of Patients of All Ages with Lysosomal Acid Lipase Deficiency (LAL-D) For More Details